The BCL2 inhibitor venetoclax is just one example of a new therapeutic agent that has allowed patients with chronic lymphocytic leukemia (CLL) to reach measurable residual disease (MRD) negativity, though complete clonal eradication has yet to be reached in these patients. Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Arnon Kater, PhD, of Universiteit Van Amsterdam, Amsterdam, Netherlands, talks about the use of venetoclax and explains the synergistic mechanism behind its combination with the BTK inhibitor ibrutinib. Prof. Kater discusses current research that aims to improve the metabolic function of T-cells in order to improve their overall function.
Novel revelations in CLL biology with venetoclax/ibrutinib
